These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 17260967)
1. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Ito G; Okai T; Fujino G; Takeda K; Ichijo H; Katada T; Iwatsubo T Biochemistry; 2007 Feb; 46(5):1380-8. PubMed ID: 17260967 [TBL] [Abstract][Full Text] [Related]
2. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358 [TBL] [Abstract][Full Text] [Related]
3. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048 [TBL] [Abstract][Full Text] [Related]
4. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. Taymans JM; Vancraenenbroeck R; Ollikainen P; Beilina A; Lobbestael E; De Maeyer M; Baekelandt V; Cookson MR PLoS One; 2011; 6(8):e23207. PubMed ID: 21858031 [TBL] [Abstract][Full Text] [Related]
5. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267 [TBL] [Abstract][Full Text] [Related]
6. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965 [TBL] [Abstract][Full Text] [Related]
7. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787 [TBL] [Abstract][Full Text] [Related]
8. The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro. Liu Z; West AB Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):274-280. PubMed ID: 27939437 [TBL] [Abstract][Full Text] [Related]
9. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties. Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236 [TBL] [Abstract][Full Text] [Related]
10. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation. Kamikawaji S; Ito G; Sano T; Iwatsubo T Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436 [TBL] [Abstract][Full Text] [Related]
11. The unconventional G-protein cycle of LRRK2 and Roco proteins. Terheyden S; Nederveen-Schippers LM; Kortholt A Biochem Soc Trans; 2016 Dec; 44(6):1611-1616. PubMed ID: 27913669 [TBL] [Abstract][Full Text] [Related]
12. The GTPase function of LRRK2. Taymans JM Biochem Soc Trans; 2012 Oct; 40(5):1063-9. PubMed ID: 22988866 [TBL] [Abstract][Full Text] [Related]
13. LRRK2 autophosphorylation enhances its GTPase activity. Liu Z; Mobley JA; DeLucas LJ; Kahn RA; West AB FASEB J; 2016 Jan; 30(1):336-47. PubMed ID: 26396237 [TBL] [Abstract][Full Text] [Related]
14. Contribution of GTPase activity to LRRK2-associated Parkinson disease. Tsika E; Moore DJ Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585 [TBL] [Abstract][Full Text] [Related]
15. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986 [TBL] [Abstract][Full Text] [Related]
17. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. Gloeckner CJ; Boldt K; von Zweydorf F; Helm S; Wiesent L; Sarioglu H; Ueffing M J Proteome Res; 2010 Apr; 9(4):1738-45. PubMed ID: 20108944 [TBL] [Abstract][Full Text] [Related]
18. Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations. Rudi K; Ho FY; Gilsbach BK; Pots H; Wittinghofer A; Kortholt A; Klare JP Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26310572 [TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152 [TBL] [Abstract][Full Text] [Related]
20. Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). Mills RD; Mulhern TD; Liu F; Culvenor JG; Cheng HC Hum Mutat; 2014 Apr; 35(4):395-412. PubMed ID: 24470158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]